Subir Goyal

18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial

Ashesh B. Jani, Eduard Schreibmann, Subir Goyal et al. · The Lancet · 2021 · 183 citations · Full text

Medicine, Nuclear Medicine, Oncology +16

Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone

Timothy M. Schmidt, Benjamin G. Barwick, Nisha S. Joseph et al. · Blood Cancer Journal · 2019 · 165 citations · Full text

Medicine, Hematology, Oncology +15

Mismatch Repair (MMR) Gene Alteration and BRAF V600E Mutation Are Potential Predictive Biomarkers of Immune Checkpoint Inhibitors in MMR-Deficient Colorectal Cancer

İbrahim Halil Şahin, Subir Goyal, Yoanna S Pumpalova et al. · The Oncologist · 2021 · 47 citations · Full text

Medicine, Molecular Genetics, Oncology +17

MERTK activation drives osimertinib resistance in EGFR-mutant non–small cell lung cancer

Dan Yan, Justus M. Huelse, Dmitri Kireev et al. · Journal of Clinical Investigation · 2022 · 45 citations · Full text

Medicine, Oncology, Pharmacology +17

Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors

Dylan J. Martini, Subir Goyal, Yuan Liu et al. · The Oncologist · 2021 · 41 citations · Full text

Medicine, Oncology, Pharmacology +17